Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Ono Racks Up 19% Revenue Rise on Positive Opdivo Sales
Ono Pharmaceutical said on November 1 that its first-half sales soared nearly 19% year on year thanks to expanding use of its immuno-oncology star Opdivo (nivolumab) and growth in royalty income from Bristol-Myers Squibb, the company’s global ally for the…
To read the full story
Related Article
- Ono Chief Touts 3-Pronged Recipe for Opdivo Comeback as I/O Pioneer
May 10, 2019
- Ono Plans to File Opdivo for 2nd-Line Esophageal Cancer by March-End
November 2, 2018
- Opdivo Sales Up 15% in April-June: Ono
August 2, 2018
- Opdivo Sales Dip 13% despite 1.5-Fold Volume Growth: Ono
May 11, 2018
BUSINESS
- CSL Behring Japan Names Edward Wright as New Chief
October 2, 2026
- Takeda Welcomes 39 Prospective 2027 Hires in Japan
October 2, 2026
- Nippon Shinyaku Reports 5-Year Efficacy Data for DMD Hopeful
October 2, 2026
- Taiho’s ASTX030 Hits PIII Goal, US Filing Planned
October 2, 2026
- Ono Moves US Venture Capital Arm to Cambridge
October 2, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…